Protocol for Bimolecular Fluorescence Complementation (BiFC) Assay

Reagents and chemicals

• Use mammalian expression plasmids encoding protein A fused to the N-terminal fluorescent fragment and protein B fused to the C-terminal fluorescent fragment; test both N- and C-terminal fusion orientations when the interaction has not already been validated because tag position can affect complementation^[2][3].

• Use cell-culture medium, serum, antibiotics when appropriate, transfection reagent or viral delivery system, and experimental drugs or stimuli only when compatible with the selected cell model; BiFC has been performed by plasmid expression and by BacMam-based mammalian delivery for PPI inhibitor screening^[3][6].

Antibodies, probes, dyes, or kits

• Use antibodies against the proteins of interest or epitope tags to confirm expression by Western blot or immunofluorescence, and use nuclear or organelle markers only when localization of the BiFC complex is being interpreted^[2][5].

• Use viability dyes or flow-cytometry-compatible live/dead markers only when BiFC is quantified by flow cytometry in drug screening or heterogeneous cell populations^[5][6].

Cells, tissues, isolated organs, organoids, or animals

• Use genetically transfectable or transducible mammalian cells, including cancer cell lines, primary neurons, inflammatory macrophages, tumor-derived cells, or dissociated organoid cells; intact organoids may be used only if delivery and imaging conditions are validated for the organoid model^[3][6].

• Use mouse tumor-derived cells or explanted tumor cells for ex vivo BiFC rather than assuming direct in vivo tumor BiFC unless a validated animal delivery and imaging system is available^[3][5].

Buffers and solutions

• Prepare sterile culture medium, phosphate-buffered saline, fixation buffer when fixed-cell imaging is required, and immunostaining buffers only when antibody-based confirmation or colocalization is included^[2][5].

• Prepare drug stocks and vehicle controls in matched solvent conditions for screening applications, because BiFC intensity can be used to identify compounds that modulate PPIs when paired with proper controls^[6].

Equipment and instruments

• Use a tissue-culture incubator, biosafety cabinet, fluorescence or confocal microscope, plate reader or flow cytometer when quantitative screening is intended, image-analysis software, and Western blot equipment for confirming fusion-protein expression^[2][5][6].

Controls

• Include a positive interaction pair, a negative interaction mutant or deletion mutant, each single BiFC fragment fusion alone, empty-vector or unrelated-protein controls, and expression controls by Western blot or immunofluorescence^[2][3][4].

• For drug screening, include vehicle control, untreated control, known inhibitor or disrupting mutant when available, and viability control so reduced BiFC signal is not misread as reduced interaction when it reflects toxicity or reduced expression^[6].

Preparation Steps

• Design fusion constructs by cloning each candidate protein in frame with complementary fluorescent fragments such as split YFP/Venus variants; include flexible linker-compatible designs and test reciprocal orientations when prior literature does not establish the best configuration^[2][3][7].
• Prefer improved Venus-based fragments when physiological 37 °C mammalian culture is required, because Venus/Cerulean fragment systems were developed to improve BiFC efficiency and reduce temperature-related limitations of earlier YFP systems^[7].
• Seed cells on imaging-compatible coverslips, chamber slides, or plates at a density that permits healthy growth and single-cell imaging; for primary neurons, macrophages, or organoid-derived cells, use only delivery methods already validated to maintain cell viability and phenotype in the specific model^[3][5][6].
• Prepare a transfection or transduction mixture containing both BiFC fusion constructs, and prepare matched control mixtures containing single fragments, noninteracting proteins, or interaction-defective mutants^[2][3][4].

Operation Steps

• Deliver both BiFC fusion constructs into the selected cells by transfection or viral transduction and culture under the normal conditions for that cell type; for mammalian drug-screening systems, BacMam-BiFC delivery has been used to express both components and quantify PPI modulation in cells^[3][6].
• Allow sufficient time for fusion-protein expression, partner interaction, fragment complementation, and fluorophore maturation before imaging; because maturation time depends on the fluorophore and system, report the exact expression and imaging interval rather than assuming a universal value^[2][3][4].
• Apply experimental stimuli, inflammatory activators, ferroptosis-related drugs, mitochondrial stressors, or anticancer compounds only when the goal is to test whether treatment changes a defined PPI; include vehicle-treated and untreated controls in parallel^[6].
• Image live cells when localization and cell physiology are the priority, or fix cells after BiFC maturation when fixed-cell immunofluorescence or antibody confirmation is required; acquire BiFC fluorescence using the excitation/emission settings appropriate for the selected fluorophore and keep imaging settings constant across comparison groups^[2][5].
• For flow-cytometry BiFC, collect fluorescence from individual viable cells and compare median fluorescence intensity or percentage of BiFC-positive cells across controls and treatments; this format is suitable for population-level quantification and screening when the signal window is validated^[5][6].
• For microscopy-based BiFC, collect matched fields across groups, avoid saturated images, and quantify fluorescence intensity per cell, percentage of BiFC-positive cells, and subcellular localization of the signal^[2][5].
• Confirm that both fusion proteins are expressed at comparable levels across experimental groups by Western blot or immunofluorescence, because reduced BiFC signal can result from reduced protein expression rather than disrupted interaction^[2][4][5].
• Validate positive BiFC findings using an independent interaction method such as co-immunoprecipitation, pull-down assay, proximity ligation, or reciprocal BiFC orientation, because BiFC complementation can stabilize complexes and may produce false-positive signals without proper controls^[2][4][5].

Data Acquisition and Analysis

• Acquire raw images or flow-cytometry files using identical acquisition settings for all samples within one experiment, and quantify BiFC as corrected cellular fluorescence intensity, percentage of BiFC-positive cells, or localization-enriched signal depending on the biological question^[2][5][6].
• Normalize BiFC signal to fusion-protein expression when expression varies, to viable cell number in plate-based assays, or to a positive-control interaction when comparing independent runs; do not interpret fluorescence intensity alone without expression and negative-control data^[2][4][6].
• Use biological replicates from independent cultures, animals, organoid passages, or primary-cell preparations when comparing biological conditions, and use technical replicate wells or fields for imaging or flow-cytometry precision^[5][6].
• Interpret a drug-induced decrease in BiFC as reduced protein proximity only when fusion-protein abundance and viability are preserved; otherwise, reduced fluorescence may reflect cytotoxicity, reduced transfection, reduced expression, or altered fluorophore maturation^[4][6].

Problem: Strong fluorescence appears in negative-control cells.

Possible Cause: spontaneous association of fluorescent fragments or overexpression-driven proximity.
Literature-supported Solution: use interaction-interface mutants, lower expression conditions, reciprocal controls, and improved Venus fragments such as I152L-containing systems that reduce self-assembly and improve signal-to-noise ratio^[2][4][8].

Problem: No BiFC signal is detected although the proteins are expected to interact.

Possible Cause: fusion orientation blocks folding, localization, or the interaction interface.
Literature-supported Solution: test N- and C-terminal fusion orientations for both proteins and confirm fusion-protein expression by Western blot or immunofluorescence before concluding that no interaction occurs^[2][3][5].

Problem: BiFC signal is weak at normal mammalian culture temperature.

Possible Cause: the fluorescent fragment pair has inefficient maturation under physiological conditions.
Literature-supported Solution: use Venus-derived fragment combinations, which were developed to improve BiFC efficiency under physiological culture conditions^[7].

Problem: BiFC-positive complexes appear in unexpected subcellular locations.

Possible Cause: the fluorescent fragment or fusion orientation perturbs protein localization or traps/stabilizes complexes.
Literature-supported Solution: compare localization with full-length fluorescent protein fusions, immunofluorescence, organelle markers, and interaction-defective mutants^[2][4][5].

Problem: Drug treatment lowers BiFC signal.

Possible Cause: true PPI disruption, cytotoxicity, reduced expression, or reduced delivery efficiency.
Literature-supported Solution: include viability measurement, expression controls, vehicle controls, and dose-response analysis before classifying the compound as a PPI inhibitor^[6].